EN DE
Watch Imagion Biosystems Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Imagion Biosystems Limited (IBX) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Imagion Biosystems Limited stock A$0.01, price A$0.01, upside +18.8%, quality 20 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU000000IBX6

IB Imagion Biosystems Limited logo Thin data Nov 10, 2026

Imagion Biosystems Limited

IBX · AU
Fairly valued, weak quality

The stock costs 16% less than our calculation considers fair.

Revenue last quarter +19% vs. a year ago.
Fair value A$0.0059 · Fairly valued
Negative equity (buybacks among others)
Mixed vs. peers (2/4)
Quality 20/100
Weak Growth (revenue 5y −30.9 %/yr in AUD)
Negative free cash flow
Narrow moat 23/100
Thin data
Estimate
Watch Imagion Biosystems Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$4.00 A$0.0050 Fair Value A$0.0059 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.0050 – A$4.00 · fair‑value band A$0.0059 – A$0.0060 · the A$0.0050 price screens below the A$0.0059 fair value. As of Nov 10, 2026.

Follow Imagion Biosystems in your weekly email

Every Wednesday you see whether Imagion Biosystems is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses.

Show moreShow less

It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry.

The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.

Stock analysis

Imagion Biosystems Limited (IBX) currently trades at A$0.0050, while our estimate is A$0.0059, so the stock looks roughly fairly valued today (gap 15.8%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0059 (bear) to A$0.0060 (bull), the price of A$0.0050 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Imagion Biosystems Limited reported revenue of A$32.4K in FY2025 versus A$233K in FY2021, a compound −38.9%/yr. Reported net income was −A$4.3M in FY2025.

Key figures

Market cap A$4.0M (≈ $2.8M) Micro · P/S ratio 6.99 · EPS (TTM) A$−0.0100 · Return on equity −2,805% · Return on assets (EBIT) −145% (5-year average) · Operating margin −331% · Revenue growth (YoY) +19.4% · Free cash flow −A$4.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 84% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 19%, IBX screens cheaper than that median.

Fair Value

Bear A$0.0059 Fair Value A$0.0059 Bull A$0.0060
Price A$0.0050 · Upside +18.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 20/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 33
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−98.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−59.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−30.9%
Start year 2020 (pandemic). Over 10 years: +19.4% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,771.7% (2020) → −11,074.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch IBX, get fair value alerts →

Compare Imagion Biosystems Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 149 stocks

Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 20 · Bottom 25%
Fair Value upside +18.8% · Top 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Growth and dividend
Revenue growth (quarter YoY) 19.4% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 6.99× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)58 · sector 12
FUTURE (revenue growth)97 · sector 40
PAST (return on equity)0 · sector 7
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)0 · sector 32

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥150.30 ¥165.32 +10% vs IBX
Illumina, Inc ILMN $214.91 $234.44 +9% vs IBX
IQVIA Holdings IQV $275.15 $299.58 +9% vs IBX
Thermo Fisher Scientific Inc TMO $718.20 $686.04 −4% vs IBX
Danaher Corporation DHR $236.11 $209.18 −11% vs IBX
IDEXX Laboratories, Inc IDXX $696.64 $496.48 −29% vs IBX
Mettler-Toledo International Inc MTD $1,751 $655.06 −63% vs IBX
Agilent Technologies, Inc A $177.88 $64.53 −64% vs IBX
Lonza Group LONN CHF 661.00 CHF 153.50 −77% vs IBX
Waters Corporation WAT $475.52 $91.26 −81% vs IBX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Imagion Biosystems Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Imagion Biosystems Limited Fair Value". https://www.fairvalue-calculator.com/stock/IBX

Frequently asked questions

Is Imagion Biosystems Limited (IBX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.0059 versus a price of A$0.0050, about +19% upside (fairly valued).
What is the fair value of IBX?
Our estimate for Imagion Biosystems Limited is A$0.0059 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.0050.
What is the quality score of IBX?
Imagion Biosystems Limited has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Imagion Biosystems Limited (IBX)?
Our calculated price target is the estimate of A$0.0059 (as of Nov 10, 2026). Cautious scenario A$0.0059, optimistic scenario A$0.0060. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Imagion Biosystems Limited stock forecast for 2026?
Our estimate puts fair value at A$0.0059, about +19% upside versus a price of A$0.0050 (fairly valued). Cautious scenario A$0.0059, optimistic scenario A$0.0060. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Imagion Biosystems Limited (IBX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Imagion Biosystems Limited it is A$0.0059 per share (as of Nov 10, 2026), against a price of A$0.0050.
Is Imagion Biosystems Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, IBX trades below its calculated fair value: price A$0.0050, fair value A$0.0059, a gap of about +19% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IBX?
No. The price is what the market pays today (A$0.0050); the fair value is what the company's own numbers justify (A$0.0059). For Imagion Biosystems Limited the two are A$0.0009 per share apart. That gap is exactly why we show both numbers side by side.
How much is Imagion Biosystems Limited worth?
The market values Imagion Biosystems Limited at about A$4.0M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.0050; our models calculate a fair value of A$0.0059 per share.
What do the bullish and bearish scenarios say about IBX?
Our models span a range for Imagion Biosystems Limited: cautious scenario A$0.0059, base A$0.0059, optimistic A$0.0060 per share (as of Nov 10, 2026, price A$0.0050). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Imagion Biosystems Limited (IBX)?
Balance-sheet figures for Imagion Biosystems Limited (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is IBX from its 52-week high?
Imagion Biosystems Limited trades at A$0.0050, about 84% below its 52-week high of A$0.0320 and at the low of A$0.0050 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0059 is for.
Which stocks are comparable to Imagion Biosystems Limited?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Imagion Biosystems Limited stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.0050, calculated fair value A$0.0059 (+19%), Quality Score 20/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Imagion Biosystems Limited currently trades 16% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Imagion Biosystems Limited (IBX)?
The closing price on Nov 11, 2026 was A$0.0050. Our estimate is A$0.0059, about +19% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Imagion Biosystems Limited right now?
The price is below even our cautious bear case (A$0.0059). The market is more pessimistic than our downside scenario. The models converge in a tight band (A$0.0059 to A$0.0060), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Imagion Biosystems Limited

How large is the market capitalisation of Imagion Biosystems Limited (IBX)?
The market capitalisation of Imagion Biosystems Limited is A$4.0M (≈ $2.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Imagion Biosystems Limited (IBX)?
The price-to-sales ratio of Imagion Biosystems Limited is 6.99 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Imagion Biosystems Limited (IBX)?
Earnings per share at Imagion Biosystems Limited are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Imagion Biosystems Limited (IBX)?
The return on equity (ROE) of Imagion Biosystems Limited is −2,805% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Imagion Biosystems Limited (IBX)?
On an EBIT basis the return on assets of Imagion Biosystems Limited is −145% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Imagion Biosystems Limited (IBX)?
The operating margin of Imagion Biosystems Limited is −331% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Imagion Biosystems Limited (IBX)?
Revenue at Imagion Biosystems Limited is growing +19.4% versus a year earlier (3y avg −59.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Imagion Biosystems Limited (IBX) generate?
The free cash flow of Imagion Biosystems Limited is −A$4.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Imagion Biosystems Limited (IBX) carry?
The net debt of Imagion Biosystems Limited is A$717K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Imagion Biosystems Limited in the live analysis

One click puts Imagion Biosystems Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.